Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.61 |
| ▸ | SOS1 | Q07889 | 7/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021159 | 0.90 | HTR6 (0.58) | HTR6SOS1HPGDSMN1; SMN2CNR1 | |
| SCHEMBL5053800 | 0.88 | HTR6 (0.73) | HTR6SOS1HPGDSMN1; SMN2CNR1 | |
| SCHEMBL5053874 | 0.83 | HTR6 (0.69) | HTR6SOS1HPGDSMN1; SMN2CNR1 | |
| SCHEMBL5021157 | 0.81 | CCR2 (0.43) | HTR6 | |
| SCHEMBL1747990 | 0.79 | HTR6 (0.68) | HTR6SOS1HPGDSMN1; SMN2CNR1 | |
| Hydrochloric Acid SCHEMBL1748809 | 0.78 | HTR6 (0.67) | HTR6SOS1HPGDSMN1; SMN2CNR1 | |
| SCHEMBL12527143 | 0.78 | HTR6 (0.64) | HTR6SOS1HPGDSMN1; SMN2CNR1 | |
| SCHEMBL5958552 | 0.77 | HTR6 (0.90) | HTR6HPGDSMN1; SMN2 | |
| SCHEMBL475383 | 0.77 | HTR6 (0.80) | HTR6SOS1HPGDSMN1; SMN2 | |
| SCHEMBL5021091 | 0.77 | HTR6 (0.65) | HTR6SOS1HPGDSMN1; SMN2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | HTR6 1/4885SOS1 3087/4885HPGD 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.